Bryce Point Capital LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bryce Point Capital LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 783 shares of the biopharmaceutical company's stock, valued at approximately $558,000.

A number of other hedge funds have also added to or reduced their stakes in REGN. Huntington National Bank boosted its stake in shares of Regeneron Pharmaceuticals by 51.9% during the 4th quarter. Huntington National Bank now owns 919 shares of the biopharmaceutical company's stock worth $655,000 after buying an additional 314 shares during the last quarter. Kesler Norman & Wride LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $316,000. Groupama Asset Managment increased its position in shares of Regeneron Pharmaceuticals by 12.7% during the 4th quarter. Groupama Asset Managment now owns 80,339 shares of the biopharmaceutical company's stock worth $56,445,000 after purchasing an additional 9,062 shares during the last quarter. Trexquant Investment LP raised its stake in shares of Regeneron Pharmaceuticals by 305.9% during the 4th quarter. Trexquant Investment LP now owns 56,625 shares of the biopharmaceutical company's stock worth $40,336,000 after purchasing an additional 42,674 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after buying an additional 155,369 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ REGN traded down $3.17 during trading hours on Tuesday, reaching $569.61. The company's stock had a trading volume of 274,277 shares, compared to its average volume of 689,832. The stock has a market cap of $62.27 billion, a P/E ratio of 14.89, a P/E/G ratio of 2.34 and a beta of 0.44. The firm has a fifty day simple moving average of $674.46 and a 200-day simple moving average of $772.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52 week low of $557.83 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.